News | May 27, 2023
Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
Several late-stage pipeline products have the potential to address some of these unmet needs
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Subscribe To Our Newsletter & Stay Updated
